Qc Technologies Inc's Business Segments

Q/C Technologies, Inc. has shifted its focus from developing therapeutic platforms, such as Isomyosamine and Supera-CBD, to energy-efficient blockchain and cryptocurrency infrastructure utilizing quantum-class laser-based computing. The company holds an exclusive global licensing agreement with LightSolver Ltd. to deploy laser processing units (LPUs), including the qc-LPU100™, which uses light properties to perform complex computations with increased speed and energy efficiency compared to traditional computing methods. The qc-LPU100 is intended for applications in cryptocurrency infrastructure, decentralized physical infrastructure networks (DePin Tokens), and AI-driven high-performance computing. Q/C Technologies aims to address blockchain challenges related to high energy consumption and scalability by integrating laser-based computing. The LPUs operate at room temperature within standard rack units and offer advantages over GPUs and quantum processing units, including enhanced blockchain security. The company acquired LPU Holdings LLC as a wholly owned subsidiary and reportable segment to support its laser-based computing operations. Currently, Q/C Technologies is focused on prototype development, validation, and benchmarking of the qc-LPU100, with commercialization contingent on successful validation, customer adoption, and capital acquisition. Its near-term strategy includes completing prototypes, expanding intellectual property, and partnering for pilot testing, while longer-term plans involve scaling deployments and establishing recurring revenue streams. The company is also considering divesting its prior therapeutic assets to fund this strategic focus.

The company's reportable segment comprises its therapeutic development programs, including Isomyosamine and Supera-CBD. Isomyosamine is a clinical-stage small molecule targeting the immunometabolic system to treat autoimmune diseases such as sarcopenia, frailty, adverse effects of diabetes and obesity treatments, rheumatoid arthritis, and inflammatory bowel disease, with an initial focus on age-related frailty and sarcopenia. It functions by regulating the release of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-17. Supera-CBD is a synthetic analog of CBD designed to address conditions such as epilepsy, pain, and anxiety/depression by acting on the CB2 receptor, opioid receptors, and the MAO type B enzyme. The company's legacy pharmaceutical business has involved preclinical testing, clinical trial planning and execution, regulatory submissions, and intellectual property development. It continues to maintain its intellectual property portfolio and certain operational capabilities. The company is currently evaluating strategic alternatives for this legacy pharmaceutical business, which may include divestitures, licensing transactions, partnerships, or other arrangements, with the objective of optimizing asset value and concentrating resources on its laser-based computing business. This legacy pharmaceutical segment faces significant risks, including clinical development uncertainty, potential adverse regulatory outcomes, and substantial capital requirements. Its future depends on the results of the company's strategic review and its ability to complete transactions or partnerships.